Close Menu

NEW YORK –  Meridian Bioscience this week completed its previously announced $49 million acquisition of Israel-based breath diagnostics firm Exalenz Bioscience. Exalenz sells the BreathID Breath Test System, a point-of-care urea breath test platform for detection of Helicobacter pylori infection.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.